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Abstract
The focus of this chapter is the relationship between the onset of depression in women and the
reproductive events of the menopause transition. Epidemiologic studies have documented that the
majority of women do not become depressed during the menopause transition. However, recent
longitudinal studies suggest that in some women, the reproductive events related to the menopause
transition could play a role in the onset of depression. No abnormality of ovarian hormones has been
identified that distinguishes women with depression from those who remain asymptomatic during
the menopause transition. Nonetheless, several findings suggest a role of ovarian hormones in the
onset of these depressions. First, episodes of depression cluster during the stage of the menopause
transition that is accompanied by estradiol withdrawal. Second, randomized controlled trials have
documented the short-term (3–6 weeks) antidepressant efficacy of estradiol in depressed
perimenopausal women. Third, experimentally induced estradiol withdrawal triggers mood
symptoms in some women. Thus, although depression is not a uniform accompaniment of the
menopause transition, in some women, age-related changes in ovarian estrogen production may alter
central nervous system function and predispose them to develop depression.
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Introduction
The focus of this chapter is the potential relationship between the onset of affective disorders
in women and the endocrinology of the menopause transition. First, we will review background
information that is relevant to this relationship, including the endocrinology of the menopause
transition and studies in both lower animals and humans demonstrating the widespread
neuroregulatory effects of ovarian steroids. Second, we will review epidemiologic studies
reporting the risks of mood disorders occurring during the menopause transition. Finally, we
will present studies examining the role of ovarian steroids in the development of depression in
women during the natural menopause transition, as well as in those with pharmacologically
induced menopause.
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Endocrinology of the Menopause Transition and the Postmenopause
The menopause is defined by the permanent cessation of menstruation for 12 months secondary
to a loss of ovarian activity. The postmenopause is characterized endocrinologically by
tonically elevated gonadotropin (follicle stimulating hormone (FSH), luteinizing hormone
(LH)) secretion, persistently low levels of ovarian steroids (estradiol, progesterone) and
relatively low (50% decrease compared to younger age groups) testosterone secretion.1 The
menopause transition and the perimenopause are the transitional periods from reproductive to
nonreproductive life.2 The average duration of the menopause transition (defined by menstrual
cycle irregularity) is estimated to be approximately 4 years, but there is considerable individual
variation in the duration of this phase of reproductive life, ranging from 0 to 11 years.3,4 During
the early stages of reproductive aging, the length of the follicular phase of the menstrual cycle
shortens,5,6 early follicular phase plasma FSH levels increase and inhibin B levels decrease.
7–9 As the menopause transition progresses, ovarian follicular depletion occurs, the ovary
becomes less sensitive to gonadotropin stimulation, and a state of relative hypoestrogenism
occurs; gonadotropin secretion is elevated across the menstrual cycle; ovulatory cycles are
fewer; and menstrual cycle irregularity ensues. However, in contrast to the postmenopause,
episodic (not tonic) gonadotropin secretion is present and both ovulation and normal
premenopausal (or at times increased) estradiol secretion may occur.2,10–12 The late
menopause transition is characterized endocrinologically by tonic elevations of plasma FSH
and sustained menstrual cycle irregularity with more prolonged periods of amenorrhea and
hypoestrogenism. The levels of several other hormones decrease with aging and accompany
these changes in reproductive function, including androgens (testosterone,
dehydroepiandrosterone (DHEA) and androstenedione), which begin to decline in the 20s and
reach peak decline during the late 40s and 50s, as do insulin-like growth factors and binding
proteins.10,13–16
Role of Ovarian Steroids in Modulating the Systems Involved in Affective
Adaptation
Neuroregulation
Results from animal studies demonstrate that ovarian steroids influence many of the
neuroregulatory systems implicated in the pathophysiology of affective disorders.17–19 Pre-
clinical studies have documented the manifold effects of ovarian steroids on neurotransmitter
system activities, including regulation of synthetic and metabolic enzyme production as well
as receptor and transporter protein activity. For example, in some, but not all, (reviewed in Ref.
20) experimental paradigms, estradiol has been observed to inhibit serotonin transporter
(SERT) mRNA,21 alter SERT protein levels and binding,20–25 increase 5-HT2A receptor
binding26 and mRNA,27 and facilitate imipramine-induced downregulation of 5-HT2 receptors
in the rat frontal cortex, an action seen to accompany antidepressant administration.28
Although, 5HT1A receptor binding is modulated by both estradiol29–35 and progesterone,25,
36–38 estradiol has been reported to both decrease activity of the 5HT1A receptor
(downregulation and uncoupling from its G-protein)39,40 and increase the expression of
5HT1A receptors. The latter action occurs by means of an interaction involving nuclear factor-
κB complexes, estrogen-receptor-α and a nonclassical estrogen response element.30
In humans, there are patterns of effects of ovarian steroids on the serotonin system similar to
those observed in animals. Menstrual cycle phase effects on the concomitants of serotonergic
stimulation include an increased prolactin secretion during the luteal phase after administration
of the serotonergic agents m-CPP41 and buspirone42 compared with the early follicular phase
and a decreased prolactin response after L-tryptophan43 or d-fenfluramine44 during the luteal
phase compared with mid-cycle. In asymptomatic women in whom a reversible menopause
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was induced by a GnRH-agonist, we observed that m-CPP-induced prolactin secretion was
increased during progesterone replacement; however, no differences in any m-CPP–stimulated
hormone measures were observed during estradiol replacement.45
Recent positron emission tomography (PET) studies in humans employing radioligands for
5HT1A receptors report both decreased46–48 and increased49 binding in depression. Both sex-
and menstrual cycle phase-related differences in 5HT1A binding (C11WAY) have been
observed by PET, with women having both greater 5HT1A binding than men (in the anterior
cingulate, frontal and temporal cortices, insula, hippocampus and dorsal raphe) and decreased
binding (in the dorsal raphe) during the follicular phase compared with the luteal phase of the
menstrual cycle.50,51 Finally, one uncontrolled study reported an increase in 5-HT2A binding
(F18 altanserin) in the anterior cingulate, dorsolateral prefrontal cortex and lateral orbital
frontal cortex during combined estrogen and progestin replacement (but not after estradiol
alone).52 Despite recent evidence suggesting the roles of 5HT1B and 5HT6 receptors in
depression, no studies in either animals or humans have examined the potential role of ovarian
steroids in the regulation of these 5HT receptor subtypes.53,54
Several nonclassical neural signaling systems also have been identified as potential mediators
of the therapeutic actions of antidepressant agents (e.g., cAMP response element binding
protein (CREB) and brain-derived neurotrophic factor (BDNF)).55 These cellular systems are
modulated by a range of therapies effective in depression (e.g., serotonergic and noradrenergic
antidepressants and electroconvulsive therapy (ECT)) and exhibit a pattern of change in
keeping with the latency to therapeutic efficacy for most antidepressants.56 For example,
antidepressants increase the expression and activity of CREB in certain brain regions (e.g.,
hippocampus)57 and regulate activity of genes with a cAMP response element in a brain region–
specific manner.56 Genes for BDNF and its receptor, trkB, have been proposed as potential
targets for antidepressant-related changes in CREB activity.56 Estradiol has been reported to
influence many of these same cellular processes. Specifically, ovariectomy has been reported
to decrease and estradiol increase, BDNF levels in the forebrain and hippocampus.58 Estrogen
also increases CREB activity59 and trkA expression60 and decreases glycogen synthase
kinase-3 β activity (Wnt pathway)61 in the rat brain, changes similar to those seen with mood
stabilizer drugs. In contrast, an estradiol-induced decrease in BDNF has been reported to
mediate estradiol's regulation of dendritic spine formation in hippocampal neurons.62 Thus,
the therapeutic potential of gonadal steroids in depression is suggested not only by their
widespread actions on neurotransmitter systems, but also by certain neuroregulatory actions
shared by both ovarian steroids and traditional therapies for depression (i.e., antidepressants,
ECT).
Neurocircuitry
Neuroimaging techniques (i.e., PET and functional magnetic resonance imaging (fMRI)) have
been employed to examine the effects of ovarian steroids or the normal menstrual cycle on
regional cerebral blood flow under conditions of brain activation. First, using PET (H2O15),
Berman et al.63 employed the Wisconsin Card Sort Test, a measure of executive function and
cognitive set shifting and observed that during conditions of GnRH agonist-induced ovarian
suppression, both estradiol and progesterone upregulated cortical activity in brain regions
(prefrontal, parietal, and temporal cortices and hippocampus) that are also reported to be
involved in the regulation of mood. Similarly, Shaywitz et al.64 employed fMRI in women
who were several years postmenopause and showed that estrogen therapy (but not placebo)
significantly increased activation in the inferior parietal lobule and right superior frontal gyrus
during verbal encoding and decreased activation in the inferior parietal lobule during nonverbal
coding. These findings are consistent with a recent report by Craig et al.,65 who observed
significantly decreased activation in the left prefrontal cortex, right precentral gyrus, anterior
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cingulate and medial frontal gyrus during verbal encoding in a group of women with GnRH
agonist-induced “menopause” for the treatment of uterine fibroid tumors. Finally, MRI studies
also have documented menstrual cycle phase-related changes in the activities of several brain
regions involved in the neurocircuitry of arousal, the stress response and reward processing,
including the amygdala, orbitofrontal cortex, and striatum.66–68 Thus, although the brain
regions potentially regulated by estradiol remain to be fully characterized, the activities in the
frontal cortex, amygdala, and hippocampus, areas subserving memory and the regulation of
affect, appear to be regulated by ovarian steroids in women.
Stress Axis
Studies in animals demonstrate that reproductive steroids also regulate basal and stimulated
hypothalamic-pituitary-adrenal (HPA) axis function. In general, low-dose, short-term
administration of estradiol inhibits HPA axis responses in ovariectomized animals,69–72 while
higher doses and longer treatment regimens enhance HPA axis reactivity to a variety of
stressors.73–75 Studies also indicate that estrogen administration decreases glucocorticoid
receptor mRNA production in the thymus76 and the pituitary.76–79 Moreover, evidence further
suggests that gonadal steroids influence the serotonergic regulation of the HPA axis by altering
the function of the 5-HT1a and 5-HT2 receptor systems in the cortex and hippocampus.80–82
Finally, interactions between glucocorticoid and estrogen response elements and their receptors
suggest additional ways by which gonadal steroids may modulate stress-related neural activity.
83 For example, estrogen and glucocorticoid receptors compete for CREB binding protein
(CBP) and glucocorticoid receptor interacting protein (GRIP), with the relative amounts of
these receptors increasing (estrogen) or decreasing (glucocorticoid receptor) transcription at
the AP-1 site.84,85
In women, the regulatory effects of changes in reproductive steroids on the HPA axis are less
well studied. Although some studies using psychological stressors identified increased
stimulated cortisol in the luteal phase,86,87 others using psychological88,89 or physiological
(e.g., insulin-induced hypoglycemia, exercise)90,91 stressors failed to find changes in HPA axis
activity across the menstrual cycle. Altemus et al.92 demonstrated that exercise-stimulated
HPA responses were increased in the mid-luteal compared with the follicular phase. However,
in contrast to a large animal literature documenting the ability of estradiol to increase HPA
axis secretion, Roca et al.93 found that exogenously administered progesterone, but not
estradiol, significantly increased exercise-stimulated vasopressin (AVP), adrenocorticotrophic
hormone (ACTH), and cortisol secretion compared with a GnRH agonist-induced hypogonadal
condition. The mechanism by which progesterone augments stimulated HPA axis activity is
currently unknown but could include the following: modulation of cortisol feedback restraint
of the axis69,94–97; neurosteroid-related downregulation of GABA receptors98; upregulation
of AVP (consistent with luteal phase reductions in the threshold for AVP release)99; and
enhancement of oxytocin-induced corticotropin-releasing hormone (CRH) secretion.100
Overall, it seems likely that multiple variables (e.g., the nature and intensity of the stressor, the
exact phase of the menstrual cycle) influence the detection of reproductive steroid regulation
of HPA axis activity.
Behavior
Behavioral studies in lower animals have documented the antidepressant-like effects of
estradiol in the forced swim test.19,101 Additionally, existing evidence suggests that the
antidepressant effects of estradiol in the forced swim test are mediated by estrogen receptor
β102–104 and can be reversed by the co-administration of a 5HT1A receptor antagonist.105,
106 Selective agonists of estrogen receptor β also have anxiolytic effects on behavior tests of
anxiety in rodents (e.g., open field or elevated plus maze) and decrease the HPA response to
stress.104,107 Finally, estrogen receptor β knock-out mice display an anxious phenotype in the
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female.35,108 Thus, behavioral studies in lower animals confirm that ovarian steroids modulate
central nervous system function and behaviors relevant to affective adaptation and stress-
responsivity.
Epidemiology of Depression during the Perimenopause
The majority of women do not develop depression during either the perimenopause or the
postmenopause. In fact, epidemiologic studies have concluded that postmenopausal women
are not at increased risk for developing depression109–120; however, in four studies,111,112,
116,117 depressive symptoms were observed more frequently in perimenopausal than
postmenopausal women. Indeed, in several other longitudinal, community-based studies, the
perimenopause (or the presence of menstrual cycle irregularity and hot flushes) was associated
with an increased risk for depression,121–126 consistent with studies of women attending
gynecology clinics.127–129 In the initial cross-sectional survey from the Study of Women's
Health Across the Nation (SWAN),123 perimenopausal women reported significantly more
“psychological distress” than either pre- or postmenopausal women (defined by self-reported
menstrual cycle status).123 In this study, “psychological distress” was employed as a proxy for
the syndrome of depression by requiring that core depressive symptoms (sadness, anxiety, and
irritability) persist for at least 2 weeks (similar to the duration criterion employed in DSM-IV).
The results of several studies published during the last 4 years have found similar results. First,
in a longitudinal study, Freeman et al.126 found an increased risk for clinically significant
depression (defined by elevated CES-D scale scores and the Primary Care Evaluation of Mental
Disorders (PRIME-MD)130) during the perimenopause compared with the pre- or
postmenopause. In these studies, the relationship between the menopause transition and the
onset of depression could have been confounded by the presence of a past history of depression
in the women studied, since a prior episode of depression increases the risk for future
recurrences. Thus, two subsequent studies examined the risk of depression in women with no
past history of depression. Cohen et al.131 evaluated the risk of depression in 460 women who
were followed prospectively for up to 7 years and who had no past history of depression. The
risk of new onset depression (defined by Structured Clinical Interview SCID-IV) in the
perimenopause was nearly twice that observed in the premenopause (adjusted OR = 1.8).
Similarly, Freeman et al.132 demonstrated a significantly increased (2½ times greater) rate of
new onset depression in women with no history of depression during the late perimenopause
compared with women who remained premenopausal. Finally, two recent reports by
Bromberger et al.133,134 demonstrate an increased incidence of first-onset and recurrent major
and minor depressive episodes during the late menopause transition and early postmenopause.
These data notwithstanding, the majority of women in these studies remained asymptomatic
throughout the perimenopause. However, these data suggest that events occurring during the
menopause transition and early postmenopause may predispose some women to develop
clinically significant depressive illness.
Endocrine Studies in Perimenopausal Depression
The stage of the menopause transition during which episodes of depression appear could
provide clues to the physiologic events accompanying the onset of depression. We have
examined the temporal linkage between the stages of the menopause transition and depression
in two studies. First, we prospectively examined asymptomatic premenopausal women with
regular menstrual cycles to determine whether the onsets of depression clustered during a
specific stage of the menopause transition. Women were followed with behavioral and
reproductive measures for an average of 5 years until 6 months to 1 year after the last menstrual
period. In a preliminary analysis of 29 women, we documented nine episodes of major or minor
depression in eight women, only two of whom had a prior depressive episode. These data
documented a clustering of depressive episodes in women during the late menopause transition
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relative to the premenopause.135 Second, we performed a cross-sectional study of 116 women
presenting to the NIMH midlife clinic for evaluation and treatment—all of whom met criteria
for perimenopause-onset major or minor depression. The majority of depressive episodes
occurred during the late menopause transition regardless of the presence of vasomotor
symptoms or a past history of depression.136 The late menopause transition is characterized
by estradiol “withdrawal” relative to either the postmenopause or the early perimenopause.2,
10 Thus, the temporal appearance of the depressions observed suggests an endocrine trigger
related to the perimenopause (estradiol withdrawal and/or recent-onset of prolonged
hypogonadism) in the onset of perimenopausal depression.
Basal Hormone Studies
Several reports indirectly support a role for abnormalities of reproductive hormones during the
perimenopause in depression: (1) lower gonadotropin levels are sometimes observed in
postmenopausal depressed women compared with asymptomatic comparison groups137–140;
(2) perimenopausal women with depressive symptoms are reported to have lower plasma
estrone levels141 than nondepressed perimenopausal women; and (3) an association has been
described between increased plasma FSH levels and depression.142 In contrast, three studies
of perimenopausal and postmenopausal women observed either no diagnosis-related
differences in plasma estradiol and FSH,143 or no correlation between plasma levels of
estrogens or androgens and severity of depressive symptoms.144,145 Similarly, in a study of
21 women with their first episode of depression occurring during the perimenopause, and 21
asymptomatic perimenopausal controls,146 we were unable to confirm previous reports of
lower basal plasma levels of LH137–140 or estrone141 in perimenopausal and postmenopausal
women with depression. Additionally, we observed no diagnosis-related differences in basal
plasma levels of FSH, estrone, testosterone, or free testosterone.
In addition to ovarian hormones, age-related differences in the function of several other
physiologic systems are observed in both animals and humans. Some of these differences may
occur coincidentally with the perimenopause and, therefore, may potentially contribute to
mood dysregulation at this time.
A role for the adrenal androgen DHEA and its sulfated metabolite (DHEA-S) in the regulation
of mood state is suggested by both its effects on neural physiology147,148 and its reported
antidepressant-like actions in some,149–152 but not all, clinical trials.153 DHEA's potential role
in the onset of depression may be particularly relevant at midlife given the declining levels of
DHEA production that occur with aging and the accelerated decrease in DHEA levels reported
in women, but not men, during midlife.154 It is possible, therefore, that declining secretion (or
abnormally low secretion) of DHEA may interact with perimenopause-related changes in
ovarian function to trigger the onset of depression in some women. Two studies146 (Rasgon
et al., personal communication) measured plasma levels of DHEA and cortisol in samples of
women with depression during the perimenopause and in nondepressed women matched for
age and reproductive status. Depressed perimenopausal women had significantly lower levels
of plasma DHEA, but not cortisol, compared with controls. These findings are consistent with
several previous studies suggesting an association between plasma DHEA levels and mood.
First, plasma DHEA levels correlated with the severity of depressive symptoms in a group of
postmenopausal women, with lower levels of DHEA associated with higher depression scores.
144 In two other studies, a positive correlation between DHEA-S plasma levels and feelings of
well-being was observed in groups of peri- and postmenopausal women,145 as well as elderly
depressed men and women.155 These differences in DHEA levels notwithstanding, there was
considerable overlap in plasma DHEA levels between perimenopausal women with and
without depression. Thus, at present, in addition to the limitations of basal hormonal measures,
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there is no consistent evidence that women who develop depression during the menopause
transition have an ovarian or adrenal hormone-deficient state.
Longitudinal Studies
Daly et al.156 evaluated mood scores and plasma FSH levels serially over a 6-week screening
phase in women presenting to the NIMH midlife clinic with perimenopausal depression. In the
group of women (n = 18) whose CES-D scores spontaneously decreased by ≥50%, we observed
an incremental decline in FSH levels at each of the four clinic visits that paralleled the
improvements in CES-D scores.156 Increased plasma FSH levels during the same 6-week
period were not consistently associated with worsening CES-D scores, nor were increased
CES-D scores associated with corresponding elevations in plasma FSH levels, whereas a more
uniform relationship was observed between mood and plasma FSH level when either measure
decreased. Thus, we identified a subgroup of women with perimenopausal depression whose
mood symptoms remitted spontaneously in association with a significant decline in
gonadotropin levels (and a suggested alteration in pituitary-ovarian function). Thus, although
cross-sectional studies suggest that perimenopausal depression is not associated with
abnormalities of ovarian function, longitudinal studies support a meaningful association
between alterations in pituitary-ovarian function and mood symptoms in these women.
Effects of Estradiol “Replacement” Therapy
An association between the endocrine events related to the perimenopause and the onset of
depression is also implicated (albeit indirectly) by reports of the mood-enhancing effects of
estradiol in depressed hypogonadal women.157 Recently, three double-blind, placebo-
controlled trials, which used similar methodologies and identical preparations of estradiol (i.e.,
17 beta estradiol), have examined the efficacy of estradiol in perimenopausal and
postmenopausal women with major or minor depressions.158–160 First, the therapeutic efficacy
of estradiol was examined in a double-blind, placebo-controlled trial in 34 perimenopausal
women (late perimenopause by STRAW criteria1) who also met standardized diagnostic
criteria for major and minor depression.158 After 3 weeks of estradiol, depression rating scale
scores were significantly decreased compared with baseline scores and significantly lower than
scores in the women receiving placebo. The therapeutic response to estradiol was observed in
women regardless of the presence of major or minor depression, a history of non-
perimenopause-related depression, or the presence of hot flushes. Finally, neither baseline nor
post-treatment plasma estradiol levels predicted the observed therapeutic response. In keeping
with recent community-based cross-sectional surveys,123 these data suggest that estrogen's
effect on depression is not solely a product of its ability to reduce the distress of hot flushes.
These findings also are consistent with data from Montgomery et al.161 and Saletu et al.,162
which document the beneficial effects of estradiol on mood in perimenopausal women
reporting depressive symptoms.
A second randomized, double-blind, placebo-controlled study by Soares et al.159 confirmed
the observations of Schmidt et al.158 Soares et al. reported a significant and beneficial effect
of estradiol replacement compared to placebo in women with perimenopause-related major
depression (as defined by the PRIME-MD)163 and, additionally, reported that baseline plasma
estradiol levels did not predict response to estrogen treatment.159 In contrast, a recent study
using a similar design to that employed in perimenopausal women158,159 failed to observe a
significant antidepressant effect of estradiol relative to placebo160 in depressed women who
were 5–10 years post natural menopause.
The evidence that younger perimenopausal, but not older postmenopausal, depressed women
respond to short-term estradiol therapy suggests that the mood disorders occurring in
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perimenopausal women are caused by changes in hormones (e.g., withdrawal or fluctuations)
rather than prolonged ovarian steroid deficiency.
Endocrine Manipulations: Induction of Estradiol Withdrawal and Hypogonadism
Several case series describe the onset of depressive symptoms after the induction of
hypogonadism by GnRH-agonists in gynecology clinic–based samples of women. For
example, both Warnock164 and Steingold165 observed that 75% and 80% of women,
respectively, experienced clinically significant depressive symptoms during GnRH agonist-
induced hypogonadism. These observations provide further support for the potential role of
the endocrine events accompanying the menopause transition in the onset of perimenopausal
depression.
We have examined the effects of estrogen withdrawal and the recent onset of hypogonadism
on mood symptoms using two strategies. First, Harsh et al.166 administered a GnRH agonist
for 2–3 months to 53 regular cycling, premenopausal women. In contrast to previous reports
from gynecology clinic-based samples, all women had the absence of current or past psychiatric
illness confirmed by a structured psychiatric diagnostic interview and completed daily
symptom ratings for 2 months prior to the study entry to confirm the absence of significant
mood or behavioral symptoms associated with their menstrual cycle. Additionally, all women
had normal gynecologic and medical exams. Mood and behavioral symptoms during GnRH-
agonist treatment were measured by the Beck Depression Inventory (BDI) and a self-report
symptom rating form completed on a daily basis. Plasma hormone measures confirmed that
the GnRH agonist suppressed the secretion of both ovarian steroids and gonadotropins. Only
three women (5.7% of the sample) reported BDI scores greater than seven (suggestive of
clinically significant symptoms of depression) and in only one of these women did the elevated
BDI scores persist beyond 2 weeks' duration. In contrast to the relative absence of depressive
symptoms in these women, we did observe the significant appearance of several symptoms,
including both daytime and nocturnal hot flushes, disturbed sleep, and diminished libido. The
latter finding is consistent with a prior study performed in a smaller sub-sample of these women
in whom significant reductions in libido (as measured by a modified Derogatis Inventory of
Sexual Functioning Scale167) were observed in approximately 30% of the sample.168 Thus, in
otherwise healthy women, the induction of neither hypogonadism nor hot flushes (with an
accompanying sleep disturbance) uniformly precipitated depressive symptoms.
In a second ongoing study, we are evaluating the effects of the acute withdrawal of estradiol
therapy in women with and without a past history of perimenopausal depression. In this study,
asymptomatic, postmenopausal women with and without a past history of depression during
the menopause transition are placed on a standard dose (100 mcg) of estradiol therapy and after
3 weeks are randomly assigned under double-blind conditions to continue to receive estradiol
(maintenance of estradiol) or placebo (estradiol withdrawal). Preliminary results suggest that
estradiol withdrawal induces depressive symptoms in women with a past history of
perimenopausal depression, but not in those without such a history. In women with a past
history of depression during the perimenopause, estradiol withdrawal is associated with a
significant increase in depressive symptoms (as measured by the CES-D scale169) compared
with those women who were maintained on estradiol therapy under double-blind conditions.
Additionally, no significant depressive symptoms emerged in the women lacking a history of
a past perimenopausal depression who were either withdrawn or maintained on estradiol
therapy. Thus, in contrast to our findings with GnRH agonist-induced hypogonadism in
premenopausal women with no past psychiatric history, estradiol withdrawal in women with
a past history of perimenopausal depression triggers mood symptoms. Additionally, in those
women who developed depression during the perimenopause, preliminary evidence suggests
a direct relationship between declining estradiol secretion, the onset of hypogonadism and the
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development of clinically significant mood symptoms. These data are consistent with those
from epidemiologic studies showing that, for a subgroup of women, the endocrine events of
the late menopause transition may represent important triggers for mood destabilization and
the onset of depression. Both the markers of this risk and the mechanisms underlying estradiol
withdrawal-induced depressive symptoms remain to be identified.
In summary, endocrine studies of depression during the menopause transition suggest the
following:
1. Depression during the menopause transition is not associated with a simple deficiency
or excess of reproductive hormones, as is the case in other reproductive endocrine-
related mood disorders.
2. Pharmacologic induction of hypogonadism and estradiol withdrawal is not uniformly
associated with depressive symptoms, but in some women, estradiol withdrawal
appears to be an important physiologic trigger for the onset of mood disturbance.
3. Similarly, based on the antidepressant efficacy of estradiol therapy, declining estradiol
secretion may play a role in the pathophysiology of depression during the menopause
transition (in contrast to depressions in the postmenopause).
Conclusions
Ovarian steroids regulate many of the signaling pathways, neurocircuits and behaviors that are
hypothesized to be abnormal in depression. Recent evidence from prospective studies suggests
that for a subgroup of women the endocrine events during the menopause transition play a role
in the onset of depression. Additionally, although perimenopausal depression is not caused by
abnormalities of basal ovarian hormone secretion, this disorder, nonetheless, may be
effectively treated with estradiol. The specificity of the relationship between the endocrine
events of the menopause transition and depression in these women is further suggested by
reports of the lack of antidepressant action of estradiol therapy in postmenopausal depressed
women. Nonetheless, studies in which menopause is induced pharmacologically demonstrate
that estradiol withdrawal and hypogonadism are sufficient to trigger depression in only a
subgroup of women. Future studies need to identify the biochemical factors and markers of
risk underlying the differences between those women who remain asymptomatic during the
menopause transition and those who develop depression. The biological underpinning of this
differential behavioral phenotype also may serve to reconcile and/or predict differences in
response to hormone therapies.
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